US Enlists San Diego Biotech for Experimental Ebola Antibody Therapy
The U.S. government has tapped San Diego biotech Mapp Biopharmaceutical to supply doses of the experimental Ebola antibody MBP134 for potential use in high-risk individuals amid a Bundibugyo outbreak; MBP134 was developed with BARDA for Sudan virus and has shown preclinical cross-protection against Bundibugyo; use would be coordinated by the FDA and is not yet approved, with supply details not disclosed.